Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Free Cash Flow (2022 - 2024)

Adial Pharmaceuticals' Free Cash Flow history spans 3 years, with the latest figure at -$1.5 million for Q4 2024.

  • For Q4 2024, Free Cash Flow rose 34.17% year-over-year to -$1.5 million; the TTM value through Dec 2024 reached -$6.9 million, down 1.7%, while the annual FY2025 figure was -$6.5 million, 6.21% up from the prior year.
  • Free Cash Flow for Q4 2024 was -$1.5 million at Adial Pharmaceuticals, up from -$1.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.2 million in Q3 2022 and bottomed at -$3.5 million in Q2 2022.
  • The 3-year median for Free Cash Flow is -$1.6 million (2023), against an average of -$1.9 million.
  • The largest YoY upside for Free Cash Flow was 52.77% in 2023 against a maximum downside of 57.25% in 2023.
  • A 3-year view of Free Cash Flow shows it stood at -$1.4 million in 2022, then plummeted by 57.25% to -$2.2 million in 2023, then soared by 34.17% to -$1.5 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Free Cash Flow are -$1.5 million (Q4 2024), -$1.7 million (Q3 2024), and -$2.1 million (Q2 2024).